Trial Profile
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Gonadotropin releasing hormone stimulants; Tamoxifen
- Indications Carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PENELOPE-B
- 05 Nov 2023 Results of Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within this study, published in the European Journal of Cancer
- 06 Jun 2023 Results assessing the potential of ctDNA analysis to predict future clinical relapse for patients enrolled in the PENELOPE-B trial, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2023 According to a NeoGenomics media release, data from a retrospective analysis of the Phase 3 PENELOPE-B study was presented in part at the 2023 ASCO Annual Meeting on Friday, June 2nd in Chicago, IL.